

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/036473 A3

(51) International Patent Classification⁷: C12N 15/12,
15/11, C07K 14/705, 16/28, C12Q 1/68, G01N 33/68

(21) International Application Number: PCT/US00/31581

(22) International Filing Date:
16 November 2000 (16.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/165,838	16 November 1999 (16.11.1999)	US
60/166,071	17 November 1999 (17.11.1999)	US
60/166,678	19 November 1999 (19.11.1999)	US
60/173,396	28 December 1999 (28.12.1999)	US
60/184,129	22 February 2000 (22.02.2000)	US
60/185,421	28 February 2000 (28.02.2000)	US
60/185,554	28 February 2000 (28.02.2000)	US
60/186,530	2 March 2000 (02.03.2000)	US
60/186,811	3 March 2000 (03.03.2000)	US
60/188,114	9 March 2000 (09.03.2000)	US
60/190,310	17 March 2000 (17.03.2000)	US
60/190,800	21 March 2000 (21.03.2000)	US
60/198,568	20 April 2000 (20.04.2000)	US
60/201,190	2 May 2000 (02.05.2000)	US
60/203,111	8 May 2000 (08.05.2000)	US
60/207,094	25 May 2000 (25.05.2000)	US

(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VOGELI, Gabriel [US/US]; 3005 First Avenue, Seattle, WA 98121 (US). WOOD, Linda, S. [US/US]; 10193 Fox Hollow, Portage, MI 49024 (US). PARODI, Luis, A. [SE/SE]; Grevgafan-24, S-115 43 Stockholm (SE). HIEBSCH, Ronald, R. [US/US]; 917 Lane Boulevard, Kalamazoo,

MI 49001 (US). LIND, Peter [SE/SE]; Borjegatan 31C, S-751 29 Uppsala (SE). SLIGHTOM, Jerry [US/US]; 3305 Lorraine Avenue, Kalamazoo, MI 49008 (US). SCHELLIN, Kathleen, A. [US/US]; 361 Jason Court, Portage, MI 49024 (US). KAYTES, Paul, S. [US/US]; 3506-D Shadow Bend Drive, Kalamazoo, MI 49004 (US). BANNIGAN, Christopher, M. [US/US]; 2411 Kopka Court, Bay City, MI 48708 (US). RUFF, Valerie [US/US]; 7301 Sandpiper Street, Portage, MI 49024 (US). SEJLITZ, Torsten [SE/SE]; Sankt Eriksgatan 59, S-112 34 Stockholm (SE). HUFF, Rita, M. [US/US]; 3627 B Avenue, West, Plainwell, MI 49080 (US).

(74) Agents: DELUCA, Mark et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
11 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN G PROTEIN-COUPLED RECEPTORS

(57) Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

WO 01/036473 A3

INTERNATIONAL SEARCH REPORT

In. International Application No

PCT/US 00/31581

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/11 C07K14/705 C07K16/28 C12Q1/68
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 686 573 A (CIVELLI OLIVIER ET AL) 11 November 1997 (1997-11-11)</p> <p>Note: 57.2% nt seq identity of SEQ ID NO:1 with SEQ ID NO:1 in 306 nt overlap (381-675:1021-724) column 3, line 41 -column 7, line 22 figures 2-5 claim 1</p> <p>---</p> <p>-/-</p>	1,3,4,8, 10,18, 27, 31-33, 36,43, 44,47, 48,53, 54,56, 57,62, 63,91

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

11 December 2001

Date of mailing of the international search report

15.01.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax. (+31-70) 340-3016

Authorized officer

van de Kamp, M

II INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EM_HUM 'Online! EMBL; ID HS20I3, AC AL035423, 12 February 1999 (1999-02-12) PEARCE A: "Human DNA sequence from clone 20I3 on chromosome Xq25-26. Contains a gene for brain mitochondrial carrier protein-1 (BMCP1), ESTs, STSs, GSSs and a CpG island" XPO02172504 Note: 100.0% nt seq identity with SEQ ID NO:1 in 1182 nt overlap (80867-82048:1-1182) page 29</p>	1-8
A	<p>WO 93 25677 A (GARVAN INST MED RES ; PIERCE KERRIE DIANE (AU); SELBIE LISA (AU); F) 23 December 1993 (1993-12-23) Note: 26.5% aa seq identity of A1 adenosine receptor with SEQ ID NO:2 in 306 aa overlap (6-302:3-293) page 2, line 15 -page 4, line 10 claims 1,4,7 figures 1,4,5</p>	40
P,X	<p>WO 00 22131 A (ARENA PHARMACEUTICALS INC ; GORE MARTIN (US); LIAW CHEN W (US); LIN) 20 April 2000 (2000-04-20) Note: 100.0% nt seq identity of SEQ ID NO:7 with SEQ ID NO:1 in 1008 nt overlap (1-1008:1146-139), 100.0% aa seq identity of SEQ ID NO:8 with SEQ ID NO:2 in 335 aa overlap (1-335:1-335) tables B,C,E claims 37-40</p>	1-66,69, 78,91-95
P,X	<p>WO 00 31258 A (ARENA PHARMACEUTICALS INC ; LIAW CHEN W (US); LIN I LIN (US); CHEN) 2 June 2000 (2000-06-02) Note: 100.0% nt seq identity of SEQ ID NO:7 with SEQ ID NO:1 in 1008 nt overlap (1-1008:1146-139), 100.0% aa seq identity of SEQ ID NO:8 with SEQ ID NO:2 in 335 aa overlap (1-335:1-335) page 17, line 4 page 24, line 17 -page 25, line 3 table A claims 13-16</p>	1-66,69, 78,91-95
	----	-/-

INT'L NATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 00 50562 A (SYNAPTIC PHARMA CORP) 31 August 2000 (2000-08-31)</p> <p>Note: 99.9% nt seq identity of SEQ ID NO:1 with SEQ ID NO:1 in 1106 nt overlap (25-1129:1182-77), 100.0% aa seq identity of SEQ ID NO:2 with SEQ ID NO:2 in 335 aa overlap (1-335:1-335)</p> <p>page 5, line 3 -page 17, line 15</p> <p>claims 1-156</p> <p>figures 1,2,5-10</p> <p>---</p>	1-66,69, 78,91-95
E	<p>EP 1 092 727 A (PFIZER LTD ;PFIZER (US)) 18 April 2001 (2001-04-18)</p> <p>Note: 100.0% nt seq identity of SEQ ID NO:1 with SEQ ID NO:1 in 1008 nt overlap (1-1008:1146-139), 99.7% aa seq identity of SEQ ID NO:2 with SEQ ID NO:2 in 335 aa overlap (1-334:1-335)</p> <p>page 2, line 31-56</p> <p>claims 1-56</p> <p>page 31</p> <p>---</p>	1-66,69, 78,91-95
E	<p>WO 01 42288 A (INCYTE GENOMICS INC ;REDDY ROOPA (US); AU YOUNG JANICE (US); BAUGH) 14 June 2001 (2001-06-14)</p> <p>Note: 100.0% nt seq identity of SEQ ID NO:67 with SEQ ID NO:1 in 1008 nt overlap (1-1008:1146-139), 100.0% aa seq identity of SEQ ID NO:28 with SEQ ID NO:2 in 335 aa overlap (1-335:1-335)</p> <p>page 5, line 34 -page 10, line 27</p> <p>tables 1-4</p> <p>claims 1-28</p> <p>---</p>	1-66,69, 78,91-95
X	<p>WO 99 37679 A (ROBISON KEITH ;GLUCKSMANN M ALEXANDRA (US); MILLENNIUM PHARM INC ()) 29 July 1999 (1999-07-29)</p> <p>Note: 66.9% nt seq identity of SEQ ID NO:1 with SEQ ID NO:185 in 981 nt overlap (156-1128:32-1005), 52.3% aa seq identity of SEQ ID NO:2 with SEQ ID NO:186 in 329 aa overlap (1-323:1-327)</p> <p>page 2, line 28 -page 3, line 9</p> <p>claims 1-26</p> <p>figures 1-3</p> <p>---</p> <p>-/-</p>	1,3,4,8, 10,18, 27, 31-33, 36,38, 40,43, 44,47, 48,53, 54,56, 57,62, 63,91

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EM-HTG 'Online! EMBL; ID AC007104, AC AC007104, 23 March 1999 (1999-03-23) STONE N E ET AL.: "Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, 16 unordered pieces" XP002185203 Note: 100.0% nt seq identity with SEQ ID NO:185 in 728 nt overlap (195066-195793:728-1) page 48</p> <p>---</p>	1-4, 8
P, X	<p>WO 00 64942 A (SMITHKLINE BEECHAM PLC ;SMITHKLINE BEECHAM CORP (US)) 2 November 2000 (2000-11-02) Note: 100.0% nt seq identity of SEQ ID NO:1 with SEQ ID NO:185 in 1092 nt overlap (61-1152:1-1092), 100.0% aa seq identity of SEQ ID NO:2 with SEQ ID NO:186 in 363 aa overlap (1-363:1-363) page 3, line 9 -page 4, line 6 claims 1-9</p> <p>---</p>	1-66, 69, 78, 91-95
E	<p>WO 01 36471 A (ARENA PHARMACEUTICALS INC ;CHEN RUOPING (US); DANG HUONG T (US); L) 25 May 2001 (2001-05-25) Note: 99.8% nt seq identity of SEQ ID NO:31 with SEQ ID NO:185 in 1092 nt overlap, 99.7% aa seq identity of SEQ ID NO:32 with SEQ ID NO:186 in 363 aa overlap page 35, line 15 -page 36, line 6 tables B,C,E-G,J claims 61-64</p> <p>---</p>	1-66, 69, 78, 91-95
X	<p>GLICKMAN M ET AL.: "Molecular cloning, tissue-specific expression, and chromosomal localization of a nerve growth factor-regulated G-protein-coupled receptor, nrg-1" MOLECULAR AND CELLULAR NEUROSCIENCES, vol. 14, August 1999 (1999-08), pages 141-152, XP002934509 ISSN: 1044-7431</p> <p>Note: 80.1% nt seq identity of nrg-1 with SEQ ID NO:77 in 1046 nt overlap (258-1303:1-1040), 85.8% aa seq identity of NRG-1 with SEQ ID NO:78 in 401 aa overlap (1-400:1-398) abstract figure 1</p> <p>---</p> <p>-/-</p>	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 19513 A (LXR BIOTECHNOLOGY INC ;ERIKSON JAMES (US); KIEFER MICHAEL (US); GO) 22 April 1999 (1999-04-22) Note: 59.5% identity of SEQ ID NO:4 with SEQ ID NO:77 in 650 nt overlap (67-707:37-680), 48.7% aa seq identity of translated SEQ ID NO:4 with SEQ ID NO:78 in 374 aa overlap (13-383:23-376) page 8, line 10 -page 9, line 33 claims 1-4 ---	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91
X	DATABASE EM_HUM 'Online! EMBL; ID AC011461, AC AC011461, 8 October 1999 (1999-10-08) DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone CTC-429L19, complete sequence" XP002185204 Note: 100.0% nt seq identity with SEQ ID NO:77 in 1197 nt overlap (41760-42956:1-1197) page 11-12 ---	1-8
P, X	WO 00 11166 A (MILLENNIUM PHARM INC) 2 March 2000 (2000-03-02) Note: 99.8% nt seq identity of SEQ ID NO:2 with SEQ ID NO:77 in 1197 nt overlap (152-1348:1-1197), 99.8% aa seq identity of SEQ ID NO:1 with SEQ ID NO:78 in 398 aa overlap (1-398:1-398) page 9, line 5 -page 10, line 24 claims 1-23 figure 1 ---	1-66, 69, 78, 91-95
E	WO 01 04139 A (MICHALOVICH DAVID ;SMITHKLINE BEECHAM PLC (GB); ELSOURBAGY NABIL) 18 January 2001 (2001-01-18) Note: 100.0% nt seq identity of SEQ ID NO:1 with SEQ ID NO:77 in 1197 nt overlap (1-1197:1-1197), 100.0% aa seq identity of SEQ ID NO:2 with SEQ ID NO:78 in 398 aa overlap (1-398:1-398) page 3, line 18 -page 4, line 19 claims 1-16 figures 1, 2 ---	1-66, 69, 78, 91-95

-/-

INTERNATIONAL SEARCH REPORT

Inten.	Serial Application No
PCT/US 00/31581	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NOMURA H ET AL.: "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors" INTERNATIONAL IMMUNOLOGY, vol. 5, no. 10, October 1993 (1993-10), pages 1239-1249, XP002911511 ISSN: 0953-8178</p> <p>Note: 65.2% nt seq identity of HM74 with SEQ ID NO:79 in 750 nt overlap (97-839:1-746), 52.2% aa seq identity of translated HM74 with SEQ ID NO:80 in 341 aa overlap the whole document</p> <p>---</p>	1,3,4,8, 10,18, 27, 31-33, 36,38, 40,43, 44,47, 48,53, 54,56, 57,62, 63,91
P,X	<p>DATABASE EM_NEW 'Online! EMBL; ID AC026333, AC AC026333, 23 March 2000 (2000-03-23)</p> <p>MUZNY D M ET AL.: "Homo sapiens chromosome 12 clone RP11-324E6, WORKING DRAFT SEQUENCE, 13 unordered pieces" XP002185205</p> <p>Note: 100.0% nt seq identity with SEQ ID NO:79 in 1041 nt overlap (15571-16611:1-1041) page 6</p> <p>---</p>	1-8
E	<p>WO 01 77320 A (BAYER AG ;XIAO YONGHONG (US)) 18 October 2001 (2001-10-18)</p> <p>Note: 100.0% nt seq identity of SEQ ID NO:1 with SEQ ID NO:79 in 1041 nt overlap (464-1504:1-1041) page 3, line 22 -page 6, line 20 figures 1,2 claims 1-17</p> <p>---</p>	1-66,69, 78,91-95
X	<p>DATABASE EM_GSS 'Online! EMBL; ID AQ888495, AC AQ888495, 11 November 1999 (1999-11-11)</p> <p>MAHAIRAS G G ET AL.: "HS_3162_B1_B01_MR CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3162 Col=1 Row=D, genomic survey sequence" XP002185206</p> <p>Note: 96.8% nt seq identity with SEQ ID NO:81 in 406 nt overlap (1-398:405-809) the whole document</p> <p>---</p> <p>-/-</p>	1-4,8

I. INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 99 29849 A (INCYTE PHARMA INC ; YUE HENRY (US); BANDMAN OLGA (US); LAL PREETI () 17 June 1999 (1999-06-17)</p> <p>Note: 24.4% aa seq identity of SEQ ID NO:3 with SEQ ID NO:82 in 316 aa overlap (23-331:2-303)</p> <p>page 3, line 14 -page 5, line 20</p> <p>claims 1-21</p> <p>figures 3,4</p>	40
P, X	<p>DATABASE EM_HUM 'Online! EMBL;</p> <p>ID AC083865, AC AC083865, 9 October 2000 (2000-10-09)</p> <p>KAUL R K ET AL.: "Homo sapiens chromosome 7 clone RP11-605P22, complete sequence" XP002185207</p> <p>Note: 100.0% nt seq identity with SEQ ID NO:81 in 2517 nt overlap (133106-135622:10-2525)</p> <p>page 36</p>	1-4, 8
X	<p>WO 96 39440 A (HUMAN GENOME SCIENCES INC ; LI YI (US); RUBEN STEVEN M (US)) 12 December 1996 (1996-12-12)</p> <p>Note: 56.9% nt seq identity of SEQ ID NO:1 with SEQ ID NO:83 in 722 nt overlap (239-949:73-779), 43.8% aa seq identity of SEQ ID NO:2 with SEQ ID NO:84 in 331 aa overlap (16-337:13-343)</p> <p>page 4, line 22 -page 6, line 20</p> <p>claims 1-20</p> <p>figure 1</p>	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91

-/-

INT'L NATIONAL SEARCH REPORT

Intern. Application No	PCT/US 00/31581
------------------------	-----------------

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 6 117 990 A (BONINI JAMES A ET AL) 12 September 2000 (2000-09-12) Note: 71.3% nt seq identity of SEQ ID NO:1 with SEQ ID NO:83 in 1089 nt overlap (39-1126:37-1124), 69.0% aa seq identity of SEQ ID NO:2 with SEQ ID NO:84 in 345 aa overlap (1-345:1-345) figures 1,2 column 1, line 37-60 claims 1-4 ---	1-4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91
T	DATABASE EM_HUM 'Online! EMBL; ID AF380192, AC AF380192, 6 July 2001 (2001-07-06) BOROWSKY B ET AL.: "Homo sapiens trace amine receptor 4 (TA4) gene, complete cds" XP002185208 Note: 100.0% nt seq identity with SEQ ID NO:83 in 1038 nt overlap (1-1038:88-1125), 100.0% aa seq identity with SEQ ID NO:84 in 345 aa overlap (1-345:1-345) the whole document -& BOROWSKY B ET AL.: "Trace amines: Identification of a family of mammalian G protein-coupled receptors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 8966-8971, XP002185201 abstract figure 4 --- -/-	
7		

I. INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 19170 A (EUROSCREEN S A ;COMMUNI DIDIER (BE); PIROTON SABINE (BE); PARMENT) 29 May 1997 (1997-05-29)</p> <p>Note: 55.3% nt seq identity of SEQ ID NO:1 with SEQ ID NO:85 in 450 nt overlap (278-726:95-540), 32.9% aa seq identity of SEQ ID NO:2 with SEQ ID NO:86 in 295 aa overlap (26-315:23-312) page 2, line 22 -page 12, line 3 claims 1-77 figures 1-11</p> <p>---</p>	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91
P, X	<p>DATABASE EM_NEW 'Online! EMBL; ID AL356486, AC AL356486, 21 May 2000 (2000-05-21) SKUCE C: "Human DNA sequence from clone RP11-721F14 on chromosome 13" XP002185209</p> <p>Note: 99.5% nt seq identity with SEQ ID NO:85 in 1020 nt overlap (4078-5094:1020-1) page 3</p> <p>---</p>	1-8
E	<p>WO 01 49847 A (WHITE DAVID ;GLUCKSMANN MARIA ALEXANDRA (US); MILLENNIUM PHARM INC) 12 July 2001 (2001-07-12)</p> <p>Note: 99.4% nt seq identity of SEQ ID NO:2 with SEQ ID NO:85 in 1020 nt overlap (291-1307:1-1020), 92.0% aa seq identity of SEQ ID NO:1 with SEQ ID NO:86 in 339 aa overlap (1-335:1-336) page 6, line 18 -page 9, line 16 claims 1-26 figure 1</p> <p>---</p> <p>-/-</p>	1-66, 68-95

IN NATIONAL SEARCH REPORT

Inten. J. Appl. No

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 859 055 A (SMITHKLINE BEECHAM CORP) 19 August 1998 (1998-08-19) Note: 61.0% nt seq identity of SEQ ID NO:1 with SEQ ID NO:87 in 743 nt overlap (944-1669:222-953), 50.8% aa seq identity of SEQ ID NO:2 with SEQ ID NO:90 in 299 aa overlap (46-341:38-336) page 3, line 13-24 claims 1-25 figure 1 ---	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 38, 40, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91
E	WO 01 72841 A (PE CORP NY) 4 October 2001 (2001-10-04) Note: 100.0% nt seq identity of SEQ ID NO:3 with SEQ ID NO:87 in 1138 nt overlap (860-1997:1-1138), 100.0% aa seq identity of transl SEQ ID NO:3 with SEQ ID NO:90 in 339 aa overlap page 7, line 12 -page 9, line 11 claims 1-23 figures 1-3 ---	1-66, 69, 78, 91-95
E	WO 00 73449 A (OGOZALEK KRISTINE L ;BOROWSKY BETH E (US); JONES KENNETH A (US); S) 7 December 2000 (2000-12-07) Note: 100.0% nt seq identity of SEQ ID NO:5 with SEQ ID NO:87 in 869 nt overlap (1-869:269-1137), 100.0% aa seq identity of SEQ ID NO:6 with SEQ ID NO:90 in 339 aa overlap (1-339:1-339) page 12, line 3 -page 27, line 15 claims 1-168 figures 5, 6 ---	1-66, 69, 78, 91-95
T	DATABASE EM_HUM 'Online! EMBL; ID AF380185, AC AF380185, 6 July 2001 (2001-07-06) BOROWSKY B ET AL.: "Homo sapiens trace amine receptor 1 (TA1) gene, complete cds" XP002185210 Note: 100.0% nt seq identity with SEQ ID NO:87 in 863 nt overlap (1-863:275-1137), 100.0% aa seq identity with SEQ ID NO:90 in 339 aa overlap (1-339:1-339) the whole document ---	-/-

INATIONAL SEARCH REPORT

Int'l. Appl. No.

PCT/US 00/31581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 859 052 A (SMITHKLINE BEECHAM CORP) 19 August 1998 (1998-08-19) Note: 54.5% nt seq identity of SEQ ID NO:1 with SEQ ID NO:91 in 1113 nt overlap (863-1919:315-1382) page 3, line 13-23 claims 1-25 figure 1 ---	1, 3, 4, 8, 10, 18, 27, 31-33, 36, 43, 44, 47, 48, 53, 54, 56, 57, 62, 63, 91
A	XU W-F ET AL.: "Cloning and characterization of human protease-activated receptor 4." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 12, 9 June 1998 (1998-06-09), pages 6642-6646, XP002185202 June 9, 1998 ISSN: 0027-8424 Note: 31.0% aa seq identity of PAR4 with SEQ ID NO:92 in 367 aa overlap (39-376:21-373) abstract figures 1,3,4 ---	40
X	DATABASE EM-HTG 'Online! EMBL; ID AC005849, AC AC005849, 23 October 1998 (1998-10-23) SMITH D R: "Homo sapiens chromosome 11 clone CIT-HSP-1337H24, *** SEQUENCING IN PROGRESS ***, 9 unordered pieces" XP002185211 Note: 99.9% nt seq identity with SEQ ID NO:91 in 1697 nt overlap (111522-113218:1696-1) page 28-29 ---	1-8
P, X	WO 00 26339 A (SMITHKLINE BEECHAM CORP) 11 May 2000 (2000-05-11) Note: 100.0% nt seq identity of SEQ ID NO:3 with SEQ ID NO:91 in 1413 nt overlap (1-1413:212-1624), 100.0% aa seq identity of SEQ ID NO:4 with SEQ ID NO:92 in 470 aa overlap (1-470:36-505) page 3, line 15-29 claims 1-14 ---	1-66, 69, 78, 91-95

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31581

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 68839 A (BAYER AG ;RAMAKRISHNAN SHYAM (US)) 20 September 2001 (2001-09-20) Note: 99.9% nt seq identity of SEQ ID NO:1 with SEQ ID NO:91 in 1697 nt overlap (383-2079:1-1696) page 5, line 3 -page 7, line 6 claims 1-16 figures 1,2	1-66,69, 78,91-95
X	WILSON S ET AL.: "Orphan G-protein-coupled receptors: the next generation of drug targets" BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. 7, December 1998 (1998-12), pages 1387-1392, XP001010584 the whole document	53,56,62
X	COWARD P ET AL: "Chimeric G proteins allow a high-throughput signalling assay of Gi-coupled receptors" ANALYTICAL BIOCHEMISTRY, vol. 270, no. 2, 1 June 1999 (1999-06-01), pages 242-248, XP000984715 ISSN: 0003-2697 abstract	53,56,62
X	WO 97 40148 A (BOUVIER MICHEL ;LOISEL THOMAS P (CA); UNIV MONTREAL L (CA); HEBERT) 30 October 1997 (1997-10-30) page 5, line 10 -page 6, line 13	53,56,62
A	JI T H ET AL.: "G protein-coupled receptors. I. Diversity of receptor-ligand interactions" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 28, 10 July 1998 (1998-07-10), pages 17299-17302, XP002173248 the whole document	53,56,62
A	WO 99 28470 A (GOODEARL ANDREW D J ;XIE MICHAEL (US); DISTEFANO PETER (US); GLUCK) 10 June 1999 (1999-06-10) page 5, line 1 -page 13, line 36 examples 1,2 claims 1-20	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/31581

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although and/or insofar as claims 47, 72-76, 78 and 79 are directed to a method of treatment of the human/animal body or to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-95 (inventions 1,2,5,6,11,27,30,32,34)
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-66, 69, 78, 91-95 (all partially)

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to SEQ ID NOs 1 or 73 and fragments thereof; said nucleic acid molecule encoding at least a portion of nGPCR-1. Corresponding vectors, transformed host cells, complementary nucleic acids, compositions, polypeptides (SEQ ID NOs 2 or 74), antibodies, and methods of use.

2. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 3 and 185, nGPCR-3, and SEQ ID NOs 4 and 186.

3. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65, 91-93 (all partially)

As invention 1, but concerning SEQ ID NO:5, nGPCR-4, and SEQ ID NO:6.

4. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65, 91-93 (all partially); 96, 97 (both completely)

As invention 1, but concerning SEQ ID NOs 7 and 75, nGPCR-5, and SEQ ID NOs 8 and 76.

5. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 9 and 77, nGPCR-9, and SEQ ID NOs 10 and 78.

6. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 11 and 79, nGPCR-11, and SEQ ID NOs 12 and 80.

7. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65, 91-93 (all partially)

As invention 1, but concerning SEQ ID NO:13, nGPCR-12, and SEQ ID NO:14.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:15, nGPCR-14, and
SEQ ID NO:16.

9. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:17, nGPCR-15, and
SEQ ID NO:18.

10. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:19, nGPCR-18, and
SEQ ID NO:20.

11. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 21 and 81,
nGPCR-16, and SEQ ID NOs 22 and 82.

12. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:23, nGPCR-17, and
SEQ ID NO:24.

13. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:25, nGPCR-20, and
SEQ ID NO:26.

14. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:27, nGPCR-21, and
SEQ ID NO:28.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

15. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:29, nGPCR-22, and
SEQ ID NO:30.

16. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:31, nGPCR-24, and
SEQ ID NO:32.

17. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:33, nGPCR-27, and
SEQ ID NO:34.

18. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:35, nGPCR-28, and
SEQ ID NO:36.

19. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:37, nGPCR-31, and
SEQ ID NO:38.

20. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:39, nGPCR-32, and
SEQ ID NO:40.

21. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:41, nGPCR-33, and
SEQ ID NO:42.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

22. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:43, nGPCR-34, and
SEQ ID NO:44.

23. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:45, nGPCR-35, and
SEQ ID NO:46.

24. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:47, nGPCR-36, and
SEQ ID NO:48.

25. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:49, nGPCR-37, and
SEQ ID NO:50.

26. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:51, nGPCR-38, and
SEQ ID NO:52.

27. Claims: 1-66, 69-95 (all partially); 67 (completely)

As invention 1, but concerning SEQ ID NOs 53 and 83,
nGPCR-40, and SEQ ID NOs 54 and 84.

28. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:55, nGPCR-41, and
SEQ ID NO:56.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

29. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:57, nGPCR-53, and
SEQ ID NO:58.

30. Claims: 1-66, 69-95 (all partially); 68 (completely)

As invention 1, but concerning SEQ ID NOs 59 and 85,
nGPCR-54, and SEQ ID NOs 60 and 86.

31. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:61, nGPCR-55, and
SEQ ID NO:62.

32. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 63, 87 and 89,
nGPCR-56, and SEQ ID NOs 64, 88 and 90.

33. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:65, nGPCR-57, and
SEQ ID NO:66.

34. Claims: 1-66, 69, 78, 91-95 (all partially)

As invention 1, but concerning SEQ ID NOs 67, 91 and 93,
nGPCR-58, and SEQ ID NOs 68, 92 and 94.

35. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

As invention 1, but concerning SEQ ID NO:69, nGPCR-59, and
SEQ ID NO:70.

36. Claims: 1-5, 8-11, 14-29, 31-40, 43-48, 51-57, 60-65,
91-93 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

As invention 1, but concerning SEQ ID NO:71, nGPCR-60, and
SEQ ID NO:72.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/US 00/31581

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5686573	A 11-11-1997	US	5427942 A	27-06-1995
WO 9325677	A 23-12-1993	AU WO EP JP	4296693 A 9325677 A1 0644935 A1 8500967 T	04-01-1994 23-12-1993 29-03-1995 06-02-1996
WO 0022131	A 20-04-2000	AU AU EP EP WO WO WO AU EP WO	6299199 A 6430799 A 1137776 A2 1121431 A1 0021987 A2 0022129 A1 0022131 A2 3790400 A 1133559 A2 0031258 A2	01-05-2000 01-05-2000 04-10-2001 08-08-2001 20-04-2000 20-04-2000 20-04-2000 13-06-2000 19-09-2001 02-06-2000
WO 0031258	A 02-06-2000	AU EP EP WO WO AU	3790400 A 1137776 A2 1133559 A2 0031258 A2 0022131 A2 6299199 A	13-06-2000 04-10-2001 19-09-2001 02-06-2000 20-04-2000 01-05-2000
WO 0050562	A 31-08-2000	US AU EP WO	6221660 B1 3003500 A 1075493 A2 0050562 A2	24-04-2001 14-09-2000 14-02-2001 31-08-2000
EP 1092727	A 18-04-2001	EP JP	1092727 A2 2001186888 A	18-04-2001 10-07-2001
WO 0142288	A 14-06-2001	AU AU WO WO	1956701 A 2575601 A 0142285 A2 0142288 A2	18-06-2001 18-06-2001 14-06-2001 14-06-2001
WO 9937679	A 29-07-1999	US AU EP WO	5945307 A 2236999 A 1056777 A1 9937679 A1	31-08-1999 09-08-1999 06-12-2000 29-07-1999
WO 0064942	A 02-11-2000	WO	0064942 A1	02-11-2000
WO 0136471	A 25-05-2001	AU WO	1769601 A 0136471 A2	30-05-2001 25-05-2001
WO 9919513	A 22-04-1999	AU WO	9794598 A 9919513 A2	03-05-1999 22-04-1999
WO 0011166	A 02-03-2000	AU EP WO	5575299 A 1105480 A1 0011166 A1	14-03-2000 13-06-2001 02-03-2000
WO 0104139	A 18-01-2001	WO	0104139 A2	18-01-2001
WO 0177320	A 18-10-2001	WO	0177320 A2	18-10-2001

I. INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31581

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9929849	A 17-06-1999		US 6063596 A AU 1620199 A EP 1037980 A1 WO 9929849 A1	16-05-2000 28-06-1999 27-09-2000 17-06-1999
WO 9639440	A 12-12-1996		CA 2224094 A1 WO 9639440 A1 AU 2699695 A EP 0832124 A1 JP 11507813 T	12-12-1996 12-12-1996 24-12-1996 01-04-1998 13-07-1999
US 6117990	A 12-09-2000		AU 4209500 A EP 1084238 A1 WO 0060081 A1	23-10-2000 21-03-2001 12-10-2000
WO 9719170	A 29-05-1997		WO 9719170 A1 CA 2235627 A1 EP 0862628 A1 JP 2000503526 T	29-05-1997 29-05-1997 09-09-1998 28-03-2000
WO 0149847	A 12-07-2001		AU 2458101 A WO 0149847 A2	16-07-2001 12-07-2001
EP 0859055	A 19-08-1998		US 5871967 A CA 2220856 A1 EP 0859055 A1 JP 10295387 A US 2001016319 A1	16-02-1999 24-07-1998 19-08-1998 10-11-1998 23-08-2001
WO 0172841	A 04-10-2001		WO 0172841 A2	04-10-2001
WO 0073449	A 07-12-2000		AU 5168700 A EP 1100896 A1 WO 0073449 A1	18-12-2000 23-05-2001 07-12-2000
EP 0859052	A 19-08-1998		US 5851798 A EP 0859052 A1 JP 10295376 A US 6133420 A US 6005074 A US 6159700 A	22-12-1998 19-08-1998 10-11-1998 17-10-2000 21-12-1999 12-12-2000
WO 0026339	A 11-05-2000		EP 1155031 A2 WO 0026339 A2	21-11-2001 11-05-2000
WO 0168839	A 20-09-2001		WO 0168839 A2	20-09-2001
WO 9740148	A 30-10-1997		AU 2501297 A CA 2252369 A1 WO 9740148 A2 EP 0901525 A2	12-11-1997 30-10-1997 30-10-1997 17-03-1999
WO 9928470	A 10-06-1999		US 5882893 A AU 1628299 A EP 1034268 A1 WO 9928470 A1 US 6093545 A	16-03-1999 16-06-1999 13-09-2000 10-06-1999 25-07-2000